BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23617728)

  • 1. Papillary carcinoma of the thyroid: high expression of COX-2 and low expression of KAI-1/CD82 are associated with increased tumor invasiveness.
    Scarpino S; Duranti E; Giglio S; Di Napoli A; Galafate D; Del Bufalo D; Desideri M; Socciarelli F; Stoppacciaro A; Ruco L
    Thyroid; 2013 Sep; 23(9):1127-37. PubMed ID: 23617728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness.
    Scarpino S; Duranti E; Stoppacciaro A; Pilozzi E; Natoli G; Sciacchitano S; Luciani E; Ruco L
    J Pathol; 2009 Aug; 218(4):487-94. PubMed ID: 19391129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).
    Mato E; González C; Moral A; Pérez JI; Bell O; Lerma E; de Leiva A
    J Mol Endocrinol; 2014 Jun; 52(3):289-300. PubMed ID: 24643400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiRNA-146b-5p upregulates migration and invasion of different Papillary Thyroid Carcinoma cells.
    Lima CR; Geraldo MV; Fuziwara CS; Kimura ET; Santos MF
    BMC Cancer; 2016 Feb; 16():108. PubMed ID: 26883911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma.
    Wang JR; Li XH; Gao XJ; An SC; Liu H; Liang J; Zhang K; Liu Z; Wang J; Chen Z; Sun W
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):427-35. PubMed ID: 23467939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentivirus-mediated shRNA interference of trefoil factor 3 blocks cell viability, migration and invasion in the papillary thyroid carcinoma cells.
    Wu J; Zhang H; Zhang W; Zhang J; Lin X; Xue G; Gao F
    Neoplasma; 2018; 65(2):169-177. PubMed ID: 29534576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing GPX3 Expression Promotes Tumor Metastasis in Human Thyroid Cancer.
    Zhao H; Li J; Li X; Han C; Zhang Y; Zheng L; Guo M
    Curr Protein Pept Sci; 2015; 16(4):316-21. PubMed ID: 25929866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD82, and CD63 in thyroid cancer.
    Chen Z; Mustafa T; Trojanowicz B; Brauckhoff M; Gimm O; Schmutzler C; Köhrle J; Holzhausen HJ; Kehlen A; Klonisch T; Finke R; Dralle H; Hoang-Vu C
    Int J Mol Med; 2004 Oct; 14(4):517-27. PubMed ID: 15375577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line.
    Jee BK; Park KM; Surendran S; Lee WK; Han CW; Kim YS; Lim Y
    Biochem Biophys Res Commun; 2006 Apr; 342(2):655-61. PubMed ID: 16488391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-338-5p promotes the growth and metastasis of malignant melanoma cells via targeting CD82.
    Long J; Luo J; Yin X
    Biomed Pharmacother; 2018 Jun; 102():1195-1202. PubMed ID: 29710538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
    Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
    J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1.
    Odintsova E; Sugiura T; Berditchevski F
    Curr Biol; 2000 Aug; 10(16):1009-12. PubMed ID: 10985391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5'-AMP-Activated Protein Kinase Regulates Papillary (TPC-1 and BCPAP) Thyroid Cancer Cell Survival, Migration, Invasion, and Epithelial-to-Mesenchymal Transition.
    Cazarin JM; Coelho RG; Hecht F; Andrade BM; Carvalho DP
    Thyroid; 2016 Jul; 26(7):933-42. PubMed ID: 27121619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.
    Fan C; Wang W; Jin J; Yu Z; Xin X
    Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
    Fang Z; Song R; Gong C; Zhang X; Ren G; Li J; Chen Y; Qiu L; Mei L; Zhang R; Xiang X; Chen X; Shao J
    Tumour Biol; 2016 Mar; 37(3):3515-26. PubMed ID: 26453115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CD9 and CD82 in papillary thyroid microcarcinoma and its prognostic significance.
    Kim T; Kim Y; Kwon HJ
    Endokrynol Pol; 2019; 70(3):224-231. PubMed ID: 30794730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin inhibits invasion and metastasis in K1 papillary thyroid cancer cells.
    Zhang CY; Zhang L; Yu HX; Bao JD; Sun Z; Lu RR
    Food Chem; 2013 Aug; 139(1-4):1021-8. PubMed ID: 23561205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD82/KAI expression prevents IL-8-mediated endothelial gap formation in late-stage melanomas.
    Khanna P; Chung CY; Neves RI; Robertson GP; Dong C
    Oncogene; 2014 May; 33(22):2898-908. PubMed ID: 23873025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of MTA1 and loss of KAI-1 and KiSS-1 expressions are associated with invasion, metastasis, and poor-prognosis of gallbladder adenocarcinoma.
    Wang W; Yang ZL; Liu JQ; Yang LP; Yang XJ; Fu X
    Tumori; 2014; 100(6):667-74. PubMed ID: 25688501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of c-Met signaling by the tetraspanin KAI-1/CD82 affects cancer cell migration.
    Takahashi M; Sugiura T; Abe M; Ishii K; Shirasuna K
    Int J Cancer; 2007 Nov; 121(9):1919-1929. PubMed ID: 17621632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.